We act for many of the world’s largest pharmaceutical companies, giving us broad and deep insights into the key trends and risks facing companies operating in the sector.
We advise on a wide range of complex cases, working with both national and international clients on high-profile and strategic matters. We have gathered significant and relevant experience of acting for leading companies in the life sciences sector on regulatory issues and we have built a track record of running a number of multi-jurisdictional matters. We also have a strong offering advising pharmaceuticals on transactions including M&A, collaborations and fundraising.
News and insights
Blog Post: 22 September 2023
The regulatory frameworks for medicines and medical devices have historically grown up on separate tracks, but increasingly, medicines and medical devices are being used together in patients as drug…
Blog Post: 06 September 2023
The European Commission published the long awaited proposals for major revision of pharmaceutical law in the European Union.
Blog Post: 30 August 2023
In increasingly complex and uncertain economic times, companies in the life sciences sector are facing unique supply chain challenges.
Blog Post: 29 August 2023
On August 29, 2023, Health and Human Services (“HHS”) announced the first ten drugs covered by Medicare Part D selected for negotiation under President Biden’s Inflation Reduction Act of 2022 (“IRA”),…